Glioblastoma (GBM) is an aggressive form of brain cancer with multiple layers of molecular and cellular heterogeneity implicated in treatment resistance and progression. Recent single cell and regional transcriptional profiling efforts have highlighted a convergence of GBM’s molecular permutations onto a small handful of reoccurring cellular states and niche-specific programs. Understanding interdependencies between these intra-tumoral molecular phenotypes is critical to addressing treatment failures and could help further focus design of combination therapies for this deadly disease.

No abstract